SAN DIEGO, May 8, 2018 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), the leader in spine technology innovation, focused
on transforming spine surgery with minimally disruptive,
procedurally-integrated solutions, today announced the Company will
officially unveil MAGEC X, the newest offering in its Early Onset
Scoliosis (EOS) procedural solutions portfolio at the POSNA
Annual Meeting in Austin,
Texas. NuVasive is a Double Diamond Sponsor of the
conference, reflecting its continued support of advancing pediatric
care.
The launch of MAGEC X is the culmination of over a decade of
research and innovation. The new and improved MAGEC X features a
strong, smart and sleek design with a new 5.0mm rod option that
offers 68 percent improved fatigue-strength performance over the
previous 4.5mm optioni. The internal rod mechanism of
the previous product generation has been redesigned with a robust
actuator seal, a reinforced locking pin and anti-jam protection.
Aesthetic improvements to the new design enhance ease-of-use by
providing visual indicators for cutting and implanting the rod.
At its core, the MAGEC system features magnetically-controlled
growing rods designed to eliminate planned distraction surgeries
from the treatment for EOS. This innovative system simplifies care
for EOS by helping to reduce the anxiety and complication risks
associated with repetitive growing-rod
surgeriesii.
"The MAGEC system continues to be the gold standard for the
minimally-invasive treatment of Early Onset Scoliosis," said
Matt Link, executive vice president,
strategy, technology and corporate development for NuVasive. "With
MAGEC X, we have found a way to take an exceptional solution to
another level through internal rod mechanism advancements to boost
performance and by providing surgeons with expanded size options.
With MAGEC X clinicians can treat a greater variety of EOS
cases—giving them a less invasive and traumatic experience as they
work to achieve a straighter spine and a higher quality of
life."
Starting in summer 2018, NuVasive will kick-off the Journey
Together Program featuring a limited warranty on MAGEC X rods
when used with cleared NuVasive procedural solutions. Through this
unique partnership with patients, families, surgeons and hospitals,
NuVasive hopes to provide a healthcare solution that maximizes the
value of EOS treatment.
During POSNA 2018, NuVasive is also showcasing RELINE Small
Stature and LessRay within its pediatric spine solutions
portfolio.
RELINE Small Stature is the first pediatric deformity fixation
solution to accept both 4.5mm and 5.0mm rods in a low-profile
tulip—eliminating the need to sacrifice strength for size in EOS
patients. The instrumentation helps surgeons gain heightened
anatomical awareness to optimize implant placement, and when paired
with the new MAGEC X 5.0mm rod, the procedural solution may
minimize the occurrence of revision surgeries.
In addition, as part of the Company's Surgical Intelligence™
platform, LessRay offers the surgeon and hospital system the
opportunity to use significantly reduced radiation imaging in the
operating room. Following a recent procedure using LessRay, Dr.
Amer Samdani, Chief of Surgery at
Shriners Hospital for Children — Philadelphia, remarked, "I was amazed that the
NuVasive LessRay technology allowed us to take less shots and
reduce the radiation emission with every shot, which has
significant impact for staff and patients of all ages."
Attendees at the POSNA Annual Meeting are encouraged to stop by
NuVasive booth # 25-26 to learn more about MAGEC X, RELINE Small
Stature, LessRay and the Company's comprehensive, industry-leading
solutions for creating better clinical outcomes for pediatric spine
procedures.
About NuVasive
NuVasive, Inc. (NASDAQ:
NUVA) is the leader in spine technology innovation, focused on
transforming spine surgery and beyond with minimally disruptive,
procedurally-integrated solutions designed to deliver reproducible
and clinically-proven surgical outcomes. The Company's portfolio
includes access instruments, implantable hardware, biologics,
software systems for surgical planning, navigation and imaging
solutions, magnetically adjustable implant systems for spine and
orthopedics, and intraoperative monitoring service offerings. With
over $1 billion in revenues, NuVasive
has an approximate 2,400 person workforce in more than 40 countries
serving surgeons, hospitals and patients. For more information,
please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions
you that statements included in this news release that are not a
description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which,
if they do not materialize or prove correct, could cause NuVasive's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. The
potential risks and uncertainties which contribute to the uncertain
nature of these statements include, among others, risks associated
with acceptance of the Company's surgical products and procedures
by spine surgeons, development and acceptance of new products or
product enhancements, clinical and statistical verification of the
benefits achieved via the use of NuVasive's products (including the
iGA® platform), the Company's ability to effectually manage
inventory as it continues to release new products, its ability to
recruit and retain management and key personnel, and the other
risks and uncertainties described in NuVasive's news releases and
periodic filings with the Securities and Exchange Commission.
NuVasive's public filings with the Securities and Exchange
Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect
events or circumstances arising after the date on which it was
made.
i Data on File
ii Yoon WW, Sedra F, Shah S, et al. Improvement of
pulmonary function in children with early-onset scoliosis using
magnetic growth rods. Spine. 2014;39 (15):1196-1202.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nuvasive-unveils-newest-additions-to-early-onset-scoliosis-portfolio-at-posna-annual-meeting-300644642.html
SOURCE NuVasive, Inc.